[177Lu]Lu-NNS309

N/A

Report date: 2025/11/21 17:16:28
NME

Base Information

Drug Name[177Lu]Lu-NNS309
Drug Alias Name[177Lu]Lu-NNS309FXX489FXX-489
ClassificationRadiation-emitting products > Radioactive therapeutic agentSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4] 
Mechanisms of ActionPositron-emission tomography enhancersFibroblast activation protein alpha modulators
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsLarge intestine neoplasmCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesPeptiDream IncNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsLarge intestine neoplasmCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A